Teva Upbeat On Partnered Biosimilars With EU Ranibizumab Set For 2022
‘We Are Addressing Some 80% Of The Value Going Off-Patent In The Coming Years’
Teva is confident that its partnered biosimilar programs – roughly half of its pipeline – will not dilute its margins, as it gears up to launch a biosimilar Lucentis product in the EU this year while pushing through other allied and internal assets in the US.
You may also be interested in...
With Samsung Bioepis already holding US and EU approvals for biosimilar ranibizumab, Swedish sponsor Xbrane Biopharma says 12-month Phase III data supports ongoing registration of the Lucentis rival in both regions.
Keeping a keen eye on costs through a multi-pronged strategy allowed Teva to bolster its margins and direct cash flow towards debt in 2021. But revenues declined and 2022 is set to be another bumpy year for the Israeli giant’s top line.
Alvotech has suffered a setback in its attempt to gain the first US FDA approval for a higher-strength biosimilar adalimumab rival to Humira, after obstacles preventing facility inspections led the agency to defer action on the firm’s AVT02 candidate.